Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate which number of lymphedema therapy treatments/week best reduces upper extremity swelling, increased arm function, and reduces the most lymphedema symptoms.


Clinical Trial Description

Complete Decongestive Therapy (CDT) is the "gold standard" in lymphedema care and has been found to be efficacious in numerous studies. These studies have varying treatment protocols of intensive phase I CDT with dosing ranging from 2x/wk for a mean of 7.5 wks to 6x/wk until a plateau in arm volumes were achieved. This variability in research does not lend itself to recommendations of evidence-based protocol use of CDT in an outpatient setting.

Although CDT is backed by efficacy studies, the daily dosing given to patients is based on anecdotal rather than evidence-based practice. Because the traditional protocol was developed from "longstanding experience," research is necessary to determine the best dosing of the intensive phase of CDT. The purpose of this study is to investigate what level of dosing in the intensive CDT phase promotes best volume reduction and increased upper extremity function in the breast cancer-related lymphedema patient population. This particular study will answer: What dosing produces best volumetric reduction and upper extremity function in the intensive phase of complete decongestive therapy for outpatients with breast cancer-related lymphedema 2x/wk for 4wks or 4x/wk for 4 wks? ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02458391
Study type Interventional
Source University of Indianapolis
Contact
Status Withdrawn
Phase N/A
Start date July 2015
Completion date July 2015

See also
  Status Clinical Trial Phase
Terminated NCT04858230 - LymphoPilot Test for Limb Lymphedema N/A
Completed NCT04575636 - MRL in the Upper Extremity N/A
Completed NCT03252145 - Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device N/A
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Completed NCT05754346 - Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema N/A
Not yet recruiting NCT06264817 - Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. N/A
Completed NCT06399458 - The Relationship Between Primary Lymphedema and Joint Hypermobility
Recruiting NCT06302361 - Lymphovenous Anastomosis for Breast Cancer Lymphedema N/A
Active, not recruiting NCT06278298 - Different Level of ECSWT in Post Mastectomy Lymphedema N/A
Completed NCT05037708 - Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer N/A
Not yet recruiting NCT02453295 - Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema N/A
Completed NCT05660590 - Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema N/A
Completed NCT04766489 - Evaluation of the Treatment Response in Breast Cancer Related Lymphedema N/A
Enrolling by invitation NCT04165512 - Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema N/A
Recruiting NCT05762224 - Comparative Effects of KT and PG on UE Lymphedema and Functional Disability After Mastectomy N/A
Recruiting NCT06082349 - The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema N/A
Recruiting NCT05142800 - Screening For BCRL In Targeted Therapy For Breast Cancer
Recruiting NCT06012786 - Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
Not yet recruiting NCT06113627 - Lymphatic Response to Resistance Exercise in Breast Cancer Survivors N/A
Completed NCT06036173 - Body Awareness and Functionality in Lymphedema